Skip to main content
ILYANG PHARMACEUTICAL CO.,LTD logo

ILYANG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 007570 ISIN · KR7007570005 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2025-09-10 Legal Proceedings Report
Country KR South Korea
Listing KO 007570

About ILYANG PHARMACEUTICAL CO.,LTD

https://www.ilyang.co.kr

Ilyang Pharmaceutical, established in 1946, is a research-oriented company that develops and manufactures a diverse portfolio of pharmaceutical products. The company focuses on developing new chemical entities (NCEs) and produces a range of medicines targeting digestive, respiratory, and circulatory system disorders, as well as neoplasms and infectious diseases. Key developments include 'Ilaprazole' (Noltec), a proton pump inhibitor for acid-related disorders, and 'Supect' (Radotinib), a treatment for chronic myeloid leukemia. Its product line also encompasses general drugs, antibiotics, anti-inflammatory agents, nutritional supplements, and well-established consumer health brands like the digestive aid 'NORUMO' and the nutritional drink 'Wonbi-D'.

Recent filings

Filing Released Lang Actions
조회공시요구(풍문또는보도)
Legal Proceedings Report Classification · 100% confidence The document is a short, formal notice from a regulatory body (KRX) requiring the company to clarify rumors or reports regarding accounting violations. It is a standard regulatory inquiry/announcement rather than a financial report or a specific corporate action like a dividend or share issue. As it does not fit into the other specific categories, it falls under the general regulatory filing category.
2025-09-10 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Single Sale/Supply Contract' amendment. It details a contract extension for a pharmaceutical supply agreement between Ilyang Pharmaceutical and R-pharm. Since this is a specific regulatory disclosure of a material contract event (a contract amendment/update) and does not fit into categories like financial reports, board changes, or dividend announcements, it falls under the general regulatory filing category.
2025-09-05 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the termination of a trust contract for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This falls under the category of company share buyback or treasury share management activities. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct classification for reports concerning the company buying back or selling its own shares.
2025-08-18 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '신탁계약해지결과보고서' (Report on the Termination of a Trust Agreement) filed by Ilyang Pharmaceutical Co., Ltd. with the Financial Supervisory Service (FSS) of South Korea. It details the termination of a trust contract used for share buybacks and the subsequent transfer of those shares to the company's treasury. This type of filing is a standard regulatory disclosure regarding share repurchase programs and their conclusion, which falls under the category of 'Transaction in Own Shares' (POS) as it reports the final status of a share buyback program.
2025-08-18 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Ilyang Pharmaceutical Co., Ltd., covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial statements, management discussion, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal announcement of a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) by Il-Yang Pharmaceutical. It details the contract value, counterparty (Public Procurement Service), and duration. Since this is a specific regulatory disclosure regarding a material business contract that does not fit into financial reporting, M&A, or other specific categories, it is classified as a general regulatory filing.
2025-06-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.